Endra Life Sciences Inc (NDRA)

$4.69 +0.04 (0.86%)
Market Cap 3.53M
Revenue (ttm) 0.00
Net Income (ttm) -11.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 11,000
Avg Vol 131,086
Day's Range N/A - N/A
Shares Out 753,000.00
Stochastic %K 84%
Beta -0.23
Analysts Sell
Price Target $30.00

Company Profile

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source comprising radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 734 335 0468
Address:
3600 Green Court, Suite 350, Ann Arbor, United States
NewsAndFilings
NewsAndFilings Apr. 2 at 12:14 PM
Yesterday's Recap: $GOGR Aligns Commercialization Roadmap and Capital Strategy Following Strategic Board Session $ADMQ Reports $5.62M Revenue $SNYR Financial Results $NDRA Financial Results
0 · Reply
D3fiant
D3fiant Apr. 1 at 9:01 PM
$NDRA anyone know why WeDull restricted trading on this company. All you can do is close out positions now?
0 · Reply
MsGrumpy
MsGrumpy Apr. 1 at 3:05 PM
$NDRA ENDRA Life Sciences Inc. reported financial results for the quarter and year ended December 31, 2025 https://www.businesswire.com/news/home/20260331142790/en/ENDRA-Life-Sciences-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update john derienzo
0 · Reply
NewsAndFilings
NewsAndFilings Apr. 1 at 12:30 PM
$NDRA ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update https://www.businesswire.com/news/home/20260331142790/en/ENDRA-Life-Sciences-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update
0 · Reply
Giants67
Giants67 Apr. 1 at 12:06 PM
$NDRA ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update https://www.businesswire.com/news/home/20260331142790/en/ENDRA-Life-Sciences-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update
0 · Reply
NewsAndFilings
NewsAndFilings Mar. 29 at 9:12 PM
Weekly Rundown: $TOON Shareholder Letter $TERS Agreement with Rhovia $RDTCF $DOSE.CN Shareholder Letter $CBDW CEO Interview $VTIX Omni One to US Marines & Named to Fast Company’s Annual List $NDRA Shareholder Updates
0 · Reply
OwlKing
OwlKing Mar. 29 at 7:43 PM
$CAR $NDLS $NDRA Ff
0 · Reply
Red2Profit
Red2Profit Mar. 28 at 9:28 PM
0 · Reply
TradeWithCreed
TradeWithCreed Mar. 27 at 7:58 PM
Looks like ticker FGI is the next micro float ticker to make a big move ! Every small float ticker has been running like crazy recently FGI starting to make its move now! Only 580k shares outstanding! 💎 Eyes on $AIRG $NAVN $GVH $NDRA small
0 · Reply
Few_erish
Few_erish Mar. 26 at 6:40 PM
$NDRA not dead at all
1 · Reply
Latest News on NDRA
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 31, 2026, 4:05 PM EDT - 4 days ago

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value

Mar 25, 2026, 8:00 AM EDT - 11 days ago

ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value

ENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care

Feb 26, 2026, 8:00 AM EST - 5 weeks ago

ENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care

ENDRA's TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use

Dec 4, 2025, 8:00 AM EST - 4 months ago

ENDRA's TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use

ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker

Nov 20, 2025, 8:00 AM EST - 4 months ago

ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker

ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results

Nov 17, 2025, 8:00 AM EST - 4 months ago

ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results

ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCA

Nov 13, 2025, 8:00 AM EST - 5 months ago

ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCA

ENDRA Life Sciences Closes Up to $14.4 Million Private Placement and Launches Crypto Treasury Strategy with $3 Million in Initial HYPE Token Holdings

Oct 23, 2025, 8:00 AM EDT - 5 months ago

ENDRA Life Sciences Closes Up to $14.4 Million Private Placement and Launches Crypto Treasury Strategy with $3 Million in Initial HYPE Token Holdings

ENDRA Life Sciences Announces At-Market Private Placement of Up to $14.4 Million to Launch Digital Asset Treasury Strategy Managed by Leading Crypto Asset Manager Arca

Oct 13, 2025, 8:00 AM EDT - 6 months ago

ENDRA Life Sciences Announces At-Market Private Placement of Up to $14.4 Million to Launch Digital Asset Treasury Strategy Managed by Leading Crypto Asset Manager Arca

ENDRA Life Sciences Provides a Business Update and Reports Second Quarter 2025 Financial Results

Aug 14, 2025, 4:05 PM EDT - 8 months ago

ENDRA Life Sciences Provides a Business Update and Reports Second Quarter 2025 Financial Results

ENDRA's Ongoing Multisite Pilot Study Reveals Important Enhancements to Boost TAEUS Liver Accuracy and Repeatability Against MRI Gold Standard

Jun 16, 2025, 8:00 AM EDT - 10 months ago

ENDRA's Ongoing Multisite Pilot Study Reveals Important Enhancements to Boost TAEUS Liver Accuracy and Repeatability Against MRI Gold Standard

ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results

May 15, 2025, 4:05 PM EDT - 11 months ago

ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results

ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies

Mar 31, 2025, 8:05 AM EDT - 1 year ago

ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies

ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

Mar 31, 2025, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

Nov 22, 2024, 8:00 AM EST - 1 year ago

ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 15, 2024, 9:24 AM EST - 1 year ago

ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update

Study Highlighting ENDRA Life Sciences' TAEUS Technology in Patients with High BMI to be Presented at AASLD's The Liver Meeting® 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Study Highlighting ENDRA Life Sciences' TAEUS Technology in Patients with High BMI to be Presented at AASLD's The Liver Meeting® 2024

ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent

Nov 6, 2024, 8:00 AM EST - 1 year ago

ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent

ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany

Oct 22, 2024, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany

Data I/O And 2 Other Stocks Under $5 Executives Are Buying

Aug 30, 2024, 8:54 AM EDT - 1 year ago

Data I/O And 2 Other Stocks Under $5 Executives Are Buying

DAIO

ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements

Aug 28, 2024, 4:17 PM EDT - 1 year ago

ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements

ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 22, 2024, 4:14 PM EDT - 1 year ago

ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update

ENDRA Life Sciences Announces Reverse Stock Split

Aug 16, 2024, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Announces Reverse Stock Split

ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024

Aug 13, 2024, 4:05 PM EDT - 1 year ago

ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024

ENDRA Life Sciences Announces Leadership Changes

Aug 13, 2024, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Announces Leadership Changes

ENDRA Life Sciences to Report Second Quarter 2024 Financial Results on August 14

Aug 7, 2024, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences to Report Second Quarter 2024 Financial Results on August 14

ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering

Jun 4, 2024, 9:21 AM EDT - 1 year ago

ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering

AM Best to Host Webinar on Engaging Defense Counsel Pre-Lawsuit

Jun 4, 2024, 9:06 AM EDT - 1 year ago

AM Best to Host Webinar on Engaging Defense Counsel Pre-Lawsuit

ENDRA Provides Update Following In-person Meeting with FDA

May 20, 2024, 8:00 AM EDT - 2 years ago

ENDRA Provides Update Following In-person Meeting with FDA

ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update

May 14, 2024, 4:05 PM EDT - 2 years ago

ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update

ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024

May 7, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024

ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents

May 2, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 28, 2024, 4:05 PM EDT - 2 years ago

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024

Mar 21, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024

ENDRA Life Sciences Installs First TAEUS System in the UK

Feb 27, 2024, 8:00 AM EST - 2 years ago

ENDRA Life Sciences Installs First TAEUS System in the UK

New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences' TAEUS System

Feb 21, 2024, 8:00 AM EST - 2 years ago

New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences' TAEUS System

ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe

Feb 14, 2024, 8:30 AM EST - 2 years ago

ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe

ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology

Nov 29, 2023, 8:00 AM EST - 2 years ago

ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology

ENDRA Life Sciences to Participate in The Benchmark Company's 12th Annual Discovery One-on-One Investor Conference

Nov 27, 2023, 8:00 AM EST - 2 years ago

ENDRA Life Sciences to Participate in The Benchmark Company's 12th Annual Discovery One-on-One Investor Conference

ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 14, 2023, 4:05 PM EST - 2 years ago

ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents

Nov 8, 2023, 8:00 AM EST - 2 years ago

ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents

ENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023

Nov 7, 2023, 4:05 PM EST - 2 years ago

ENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023

ENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD's The Liver Meeting® 2023

Nov 6, 2023, 8:00 AM EST - 2 years ago

ENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD's The Liver Meeting® 2023

Abstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023

Sep 7, 2023, 8:00 AM EDT - 2 years ago

Abstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023

ENDRA Life Sciences' TAEUS De Novo Submission Advances to Next Stage of Review with FDA

Aug 30, 2023, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences' TAEUS De Novo Submission Advances to Next Stage of Review with FDA

ENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European Patents

Aug 23, 2023, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European Patents

ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update

Aug 14, 2023, 4:05 PM EDT - 2 years ago

ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update

ENDRA Life Sciences Submits De Novo Request for its TAEUS® System Liver Fat Application to the U.S. FDA

Aug 14, 2023, 1:30 PM EDT - 2 years ago

ENDRA Life Sciences Submits De Novo Request for its TAEUS® System Liver Fat Application to the U.S. FDA

ENDRA Life Sciences to Report Second Quarter 2023 Financial Results on August 14, 2023

Aug 1, 2023, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences to Report Second Quarter 2023 Financial Results on August 14, 2023

ENDRA Life Sciences Announces Adjournment of 2023 Annual Meeting of Stockholders to July 25, 2023

Jul 6, 2023, 4:45 PM EDT - 2 years ago

ENDRA Life Sciences Announces Adjournment of 2023 Annual Meeting of Stockholders to July 25, 2023

NewsAndFilings
NewsAndFilings Apr. 2 at 12:14 PM
Yesterday's Recap: $GOGR Aligns Commercialization Roadmap and Capital Strategy Following Strategic Board Session $ADMQ Reports $5.62M Revenue $SNYR Financial Results $NDRA Financial Results
0 · Reply
D3fiant
D3fiant Apr. 1 at 9:01 PM
$NDRA anyone know why WeDull restricted trading on this company. All you can do is close out positions now?
0 · Reply
MsGrumpy
MsGrumpy Apr. 1 at 3:05 PM
$NDRA ENDRA Life Sciences Inc. reported financial results for the quarter and year ended December 31, 2025 https://www.businesswire.com/news/home/20260331142790/en/ENDRA-Life-Sciences-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update john derienzo
0 · Reply
NewsAndFilings
NewsAndFilings Apr. 1 at 12:30 PM
$NDRA ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update https://www.businesswire.com/news/home/20260331142790/en/ENDRA-Life-Sciences-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update
0 · Reply
Giants67
Giants67 Apr. 1 at 12:06 PM
$NDRA ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update https://www.businesswire.com/news/home/20260331142790/en/ENDRA-Life-Sciences-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update
0 · Reply
NewsAndFilings
NewsAndFilings Mar. 29 at 9:12 PM
Weekly Rundown: $TOON Shareholder Letter $TERS Agreement with Rhovia $RDTCF $DOSE.CN Shareholder Letter $CBDW CEO Interview $VTIX Omni One to US Marines & Named to Fast Company’s Annual List $NDRA Shareholder Updates
0 · Reply
OwlKing
OwlKing Mar. 29 at 7:43 PM
$CAR $NDLS $NDRA Ff
0 · Reply
Red2Profit
Red2Profit Mar. 28 at 9:28 PM
0 · Reply
TradeWithCreed
TradeWithCreed Mar. 27 at 7:58 PM
Looks like ticker FGI is the next micro float ticker to make a big move ! Every small float ticker has been running like crazy recently FGI starting to make its move now! Only 580k shares outstanding! 💎 Eyes on $AIRG $NAVN $GVH $NDRA small
0 · Reply
Few_erish
Few_erish Mar. 26 at 6:40 PM
$NDRA not dead at all
1 · Reply
NewsAndFilings
NewsAndFilings Mar. 26 at 12:21 PM
Yesterday's Recap: $GOGR Appoints Water Technology Innovator Grant Page $BMTM Announces Fourth Quarter and Full-Year 2025 Financial Results $NDRA Initiates Review of Strategic Alternatives to Maximize Shareholder Value
0 · Reply
dndodd
dndodd Mar. 25 at 3:58 PM
$NDRA $NDRA BS on the strategic review they have considered all of these alternatives for years. The whole plan from the beginning was to sell this company but no one has been interested. Stick a fork in it is over.
0 · Reply
MsGrumpy
MsGrumpy Mar. 25 at 2:40 PM
$NDRA ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value https://www.businesswire.com/news/home/20260325586453/en/ENDRA-Life-Sciences-Initiates-Review-of-Strategic-Alternatives-to-Maximize-Shareholder-Value
0 · Reply
NewsAndFilings
NewsAndFilings Mar. 25 at 1:07 PM
$NDRA ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value https://www.businesswire.com/news/home/20260325586453/en/ENDRA-Life-Sciences-Initiates-Review-of-Strategic-Alternatives-to-Maximize-Shareholder-Value
0 · Reply
Stock_Catcher
Stock_Catcher Mar. 25 at 12:31 PM
$NDRA ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value
0 · Reply
DARKP00L
DARKP00L Mar. 25 at 12:27 PM
$NDRA 08:25 on Mar. 25 2026 Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times #tradeideas
0 · Reply
DARKP00L
DARKP00L Mar. 25 at 12:26 PM
$NDRA 08:25 on Mar. 25 2026 Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times #tradeideas
0 · Reply
DARKP00L
DARKP00L Mar. 25 at 12:25 PM
$NDRA 08:05 on Mar. 25 2026 ENDRA Life Sciences Initiates Review Of Strategic Alternatives #tradeideas
0 · Reply
DARKP00L
DARKP00L Mar. 25 at 12:24 PM
$NDRA 07:55 on Mar. 25 2026 Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending #tradeideas
0 · Reply
Giants67
Giants67 Mar. 25 at 12:23 PM
$NDRA ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value https://www.businesswire.com/news/home/20260325586453/en/ENDRA-Life-Sciences-Initiates-Review-of-Strategic-Alternatives-to-Maximize-Shareholder-Value
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 25 at 12:15 PM
$NDRA (halted pre) ENDRA puts sale, merger and asset options on the table https://ooc.bz/l/97137
0 · Reply
TA_Kongen
TA_Kongen Mar. 25 at 12:01 PM
$NDRA ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value LOL Why halt for this pos headline.
0 · Reply